Published on: August 19, 2017
by Amanda Oldt for Healio:
Recent findings suggested the serotonin system may be an effective target for prevention and treatment of mild cognitive impairment.
“Now that we have more evidence that serotonin is a chemical that appears affected early in cognitive decline, we suspect that increasing serotonin function in the brain could prevent memory loss from getting worse and slow disease progression,” Gwenn S. Smith, PhD, of Johns Hopkins University School of Medicine, said in a press release.
To assess the role of serotonin in mild cognitive impairment, researchers conducted MRI and high-resolution PET among 28 individuals with mild cognitive impairment and 29 healthy, cognitively normal controls. Mean age was approximately 66 years.
Serotonin transporter availability was lower among participants with mild cognitive impairment in cortical and limbic areas typically affected by Alzheimer’s disease and sensory and motor areas relatively unassociated with the disorder, according to researchers.
Reduction in serotonin transporter among participants with mild cognitive impairment was greater than grey matter atrophy or reductions in regional cerebral blood flow, compared with controls.
Lower cortical serotonin transporters were associated with poorer auditory-verbal and visual-spatial memory in mild cognitive impairment but not among controls.
“The results of the present study demonstrate lower [serotonin transporters] in cortical, striatal, thalamic and limbic regions in [mild cognitive impairments] relative to controls. Grey matter atrophy and reductions in regional cerebral blood flow in mild cognitive impairment compared to controls was more localized and less statistically robust than the reductions in [serotonin transporters]. The reduction in [serotonin transporters] is associated with greater impairment in auditory-verbal and visual-spatial memory in [mild cognitive impairments],” the researchers wrote. “Studies are in progress to determine whether serotonin degeneration may be involved in the transition from [mild cognitive impairments] to dementia and to relate serotonin degeneration to other aspects of [Alzheimer’s disease] neuropathology (eg, beta-amyloid and tau).”
Thanks to the ongoing support of our partner Brain Canada, and The Citrine Foundation of Canada, Women’s Brain Health Initiative’s newest edition of MIND OVER MATTER has just been published. Loaded with interesting science-based articles, MIND OVER...
On December 2nd, in celebration of Women’s Brain Health Day, join thousands of others and take part in the Stand Ahead® Memory Challenge to stand up against research bias and stand ahead for women’s brain...
YOU’RE INVITED! On December 2nd, the second annual Women’s Brain Health Day, take the memory challenge and help us combat brain-aging diseases that disproportionately affect women. Join CTV’s Pattie Lovett-Reid and Anne-Marie Mediwake, along...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.